Cyted Health Raises €37.5M Series B for Oesophageal Cancer Diagnostics

Cambridge-based Cyted Health secured €37.5 million in its Series B financing. EQT Life Sciences, Advent Life Sciences, and British Business Bank led the round. This funding will accelerate the company's ongoing US expansion.

Cyted Health, a British gastrointestinal molecular diagnostics company, focuses on improving early detection and prevention of oesophageal adenocarcinoma. The company pioneers minimally invasive cell collection coupled with proprietary biomarker discovery. Furthermore, its diagnostic platform has conducted over 35,000 tests.

The Series B financing will accelerate commercial expansion of Cyted's diagnostics platform in the US. It will also consolidate existing commercial success across the UK. Additionally, the company plans to expand its portfolio of advanced medical diagnostics tests.

Advancing Early Cancer Detection

Founded in 2020, Cyted Health developed the FDA 510(k)-cleared EndoSign device for minimally invasive esophageal cell collection. This technology, alongside advanced molecular testing, detects pre-cancerous, cancerous, and inflammatory esophageal conditions. Companies like Exact Sciences and Guardant Health also operate in the broader cancer diagnostics space.

Oesophageal cancer remains one of the deadliest cancers globally. Its survival rate is only 20%. This investment supports critical cancer research and early intervention.

Morningside and BGF, existing investors, continued their support in this round. Cyted's DETECT-ME clinical validation study, enrolling US patients since March 2025, further validates its newest assays.